| Symbol | LCTX |
|---|---|
| Name | LINEAGE CELL THERAPEUTICS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | BIOMED |
| Address | 2173 SALK AVENUE, SUITE 200, CARLSBAD, California, 92008, United States |
| Telephone | 03-6073777 |
| Fax | 03-6073778 |
| info@biotimeinc.com | |
| Website | www.lineagecell.com |
| Incorporation | USA |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | TASE;NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000876343 |
| Description | Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The companys pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineages product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures. Additional info from NASDAQ: |
The companys financial results for the First quarter of 2026 were reported abroad
Read more(30% Negative) LINEAGE CELL THERAPEUTICS INC. (LCTX) Reports Q2 2026 Financial Results
Read moreLineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Read moreLineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026
Read moreOpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026
Read moreFORM 10-K- Annual report which provides a comprehensive overview of the company for the past year
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06841770 | A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 i… | Phase1 | Spinal Cord Injury Cervical | Recruiting | 2025-06-30 | 2037-06-30 | ClinicalTrials.gov |
| NCT05975424 | LTFU Study of Subjects With Cervical SCI Who Received AST-OPC1 | — | Spinal Cord Injuries | Active_Not_Recruiting | 2018-06-13 | 2033-01-14 | ClinicalTrials.gov |
| NCT02302157 | Dose Escalation Study of AST-OPC1 in Spinal Cord Injury | Phase1 | Cervical Spinal Cord Injury | Completed | 2015-03-01 | 2018-12-01 | ClinicalTrials.gov |
| NCT05919563 | LTFU Study of Subjects Who Received GRNOPC1 | — | Spinal Cord Injuries | Active_Not_Recruiting | 2011-10-06 | 2026-12-12 | ClinicalTrials.gov |
| NCT01217008 | Safety Study of GRNOPC1 in Spinal Cord Injury | Phase1 | Spinal Cord Injury | Completed | 2010-10-01 | 2013-07-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| GRNOPC1 | Other | Phase PHASE1 | Spinal Cord Injury | COMPLETED | NCT01217008 |
| AST-OPC1 | Other | Phase PHASE1 | Cervical Spinal Cord Injury | COMPLETED | NCT02302157 |
| Magnetic Resonance Imaging (MRI) | Other | Preclinical | Spinal Cord Injuries | ACTIVE_NOT_RECRUITING | NCT05975424 |
| Magnetic Resonance Imaging (MRI) | Other | Preclinical | Spinal Cord Injuries | ACTIVE_NOT_RECRUITING | NCT05919563 |
| OPC1 | Other | Phase PHASE1 | Spinal Cord Injury Cervical | RECRUITING | NCT06841770 |
| OPC1 | BIOLOGICAL | Phase PHASE1 | Spinal Cord Injury Cervical | RECRUITING | NCT06841770 |
| AST-OPC1 | BIOLOGICAL | Phase PHASE1 | Cervical Spinal Cord Injury | COMPLETED | NCT02302157 |
| GRNOPC1 | BIOLOGICAL | Phase PHASE1 | Spinal Cord Injury | COMPLETED | NCT01217008 |